Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
- 19 January 2021
- Vol. 70 (10), 1809-1811
- https://doi.org/10.1136/gutjnl-2020-323805
Abstract
No abstract availableKeywords
Funding Information
- the Wallace McCain Centre for Pancreatic Cancer supported by the Princess Margaret Cancer Foundation (Not applicable (no grant number for this Funder))
- Ontario Institute for Cancer Research (Not applicable (no grant number for this Funder))
- the Pancreatic Cancer Canada Foundation (Not applicable (no grant number for this Funder))
- the Terry Fox Research Institute, the Canadian Cancer Society Research Institute (Not applicable (no grant number for this Funder))
- The Canadian Friends of the Hebrew University (Not applicable (no grant number for this Funder))
- Fondazione Cariverona: Oncology Biobank Project “Antonio Schiavi” (prot. 203885/2017)
- Associazione Italiana per la Ricerca sul Cancro (12182)
- Fondazione Italiana Malattie Pancreas (J38D19000690001)
This publication has 15 references indexed in Scilit:
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2020
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerThe New England Journal of Medicine, 2019
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal AdenocarcinomaJAMA Oncology, 2019
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approachAnnals of Oncology, 2019
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic CancerThe New England Journal of Medicine, 2019
- Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersGastroenterology, 2019
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the IndicationThe New England Journal of Medicine, 2017
- Integrated Genomic Characterization of Pancreatic Ductal AdenocarcinomaCancer Cell, 2017
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon CancerThe New England Journal of Medicine, 2003